ASX small and mid cap conference presentation, page-2

The potential market for Gen 2 is just sooooo big. If we just do some basic maths on a part of it (very conservatively) you get the general picture and hopefully see the potential.

Let’s assume an $80k sale price for Gen 2.
Lets assume 50% penetration of the 60k road and air ambulances in the US.
Let’s assume an average of 1 scan per day (May be more or less - not sure).
Scans for Gen 2 are expected to yield $50 per scan per patient.

Capital sales (although I know it may be sold via an all inclusive subscription model) - would be $2.4 billion.
Scans would be $50 a day x 30000 x 365 days a year = $550 Million approx of recurring revenue per year at gross margins potentially greater than 80%.

This is a very small subset, US only, Gen 2 only, one indication only and very conservative numbers.

When you actually start to include Gen 1, the major countries, multiple indications, then Gen 2, major countries, multiple indications and then on top of that you add non brain related potential and the numbers get too big for some people to take them seriously.

However, for those with the patience, the foresight, the guts, the belief, willingness to research, and the conviction to hold and add though peaks and troughs this company could one day be seriously huge.

This is just the very beginning.

DYOR, not advice.